Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
Answer:
The lectin pathway or lectin complement pathway is a type of cascade reaction in the complement system, similar in structure to the classical complement pathway, in that, after activation, it proceeds through the action of C4 and C2 to produce activated complement proteins further down the cascade.
Seaweed is a type of algae.
Explanation: Seaweeds are a group of photoautotrophic, multi-cellular algae occurring in marine environments.
Answer:
Explanation:
Two reactions take place that produce raw materials for the dark stage:
- Light energy splits the water molecules into <em>hydrogen</em> and <em>oxygen</em>
- This process is called <u>photolysis </u>
The hydrogen is taken up by a hydrogen acceptor called Nicotinamide adenine dinucleotide phosphate (NADP) while oxygen is released as a by-product .
2 H₂O(l) --------->light energy -------> 4 H + O₂ (photolysis
)
Light energy strikes the chlorophyll molecules and sets in motion a series of reactions resulting in the production of a high energy molecule called <em>Adenosine Triphosphate</em> (ATP)
Hope this helps.
